First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Saved in:
| Title: | First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. |
|---|---|
| Authors: | Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan., Powderly J; Carolina BioOncology Institute, Huntersville, NC, United States., Abdul Razak A; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada., LoRusso P; Yale Cancer Center, Yale University, New Haven, CT, United States., Miller KD; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Kao S; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Kongpachith S; AbbVie Bay Area, South San Francisco, CA, United States., Tribouley C; AbbVie Bay Area, South San Francisco, CA, United States., Graham M; AbbVie Bay Area, South San Francisco, CA, United States., Stoll B; AbbVie Bay Area, South San Francisco, CA, United States., Patel M; AbbVie Bay Area, South San Francisco, CA, United States., Sahtout M; AbbVie Bay Area, South San Francisco, CA, United States., Blaney M; AbbVie Bay Area, South San Francisco, CA, United States., Leibman R; AbbVie Bay Area, South San Francisco, CA, United States., Golan T; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel., Tolcher A; New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2024 Oct 29; Vol. 14, pp. 1376551. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
